Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis
Authors:
Open Access
- 25 March 2011
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 5 (4) , 918-926
Abstract
Purpose The combination of hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogues has been accepted as the best treatment to control hepatitis B recurrence after orthotopic liver transplantation (OLT). However, the optimal dose of HBIg remains unclear. We have previously reported that high-dose HBIg in the early period followed by low-dose HBIg with nucleos(t)ide analogues offers reliable and cost-effective control of hepatitis B recurrence. The aim of this study was to investigate intrahepatic hepatitis B virus (HBV) reinfection status with our clinically successful protocol. Methods We quantified levels of intrahepatic HBV covalently closed circular (ccc) deoxyribonucleic acid (DNA) and serum hepatitis B core-related antigen (HBcrAg), a new serological marker that can estimate intrahepatic cccDNA levels. Nucleos(t)ide analogues were administered in all cases. Results No patients showed recurrence of hepatitis B surface antigen (HBsAg) or HBV-DNA. However, HBV, cccDNA, and HBcrAg were positive in 57% and 48% of patients after OLT, respectively. Pre-OLT serum HBV-DNA and HBcrAg levels correlated linearly with post-OLT cccDNA levels (r = 0.534, P < 0.05, and r = 0.634, P < 0.05, respectively). High serum HBV-DNA and HBcrAg levels, particularly with >3 log10 copies/mL and >4 log10 IU/mL, respectively, at the time of OLT, were associated with high levels of post-OLT cccDNA. Even with our successful protocol, nearly half of patients showed HBV reinfection. Conclusions Patients with high serum HBV-DNA and HBcrAg levels before OLT (particularly >3 log10 copies/mL and >4 log10 IU/mL, respectively) should be followed with care for HBV recurrence.Keywords
This publication has 31 references indexed in Scilit:
- Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patientsJournal of Medical Virology, 2008
- Short-Term High-Dose Followed by Long-Term Low-Dose Hepatitis B Immunoglobulin and Lamivudine Therapy Prevented Recurrent Hepatitis B After Liver TransplantationTransplantation, 2007
- Hepatitis B Virus DNA-negative Dane Particles Lack Core Protein but Contain a 22-kDa Precore Protein without C-terminal Arginine-rich DomainJournal of Biological Chemistry, 2005
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004
- Hbv Dna Persistence 10 Years After Liver Transplantation Despite Successful Anti–Hbs Passive ImmunoprophylaxisHepatology, 2003
- A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantationJournal of Hepatology, 2003
- A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantationLiver Transplantation, 2001
- Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection ModelAntimicrobial Agents and Chemotherapy, 2000
- Hepatitis B virus reinfection after orthotopic liver transplantationJournal of Hepatology, 1992
- Liver transplantation in HBs antigen (HBsAg) carriersJournal of Hepatology, 1991